近日,上海交通大学章雪晴教授、新泽西理工学院许晓阳教授团队合作,在Nature Communications期刊发表了题为:mRNA lipid nanoparticle-mediated pyroptosis sensitizes immunologically cold tumors to checkpoint immunotherapy 的研究论文。 该研究提出了一种基于mRNA的细胞焦亡纳米药物治疗方法,它能够启动癌症免疫周期,将冷肿瘤转化为...
近日,上海交通大学章雪晴教授、新泽西理工学院许晓阳教授团队合作,在 Nature Communications 期刊发表了题为:mRNA lipid nanoparticle-mediated pyroptosis sensitizes immunologically cold tumors to checkpoint immunotherapy 的研究论文。 该研究提出了一种基于mRNA的细胞焦亡纳米药物治疗方法,它能够启动癌症免疫周期,将冷肿瘤转化...
近日,上海交通大学章雪晴教授、新泽西理工学院许晓阳教授团队合作,在 Nature Communications 期刊发表了题为:mRNA lipid nanoparticle-mediated pyroptosis sensitizes immunologically cold tumors to checkpoint immunotherapy 的研究论文。 该研究提出了一种基于mRNA的细胞焦亡纳米药物治疗方法,它能够启动癌症免疫周期,将冷肿瘤转化...
Gasdermin-mediated pyroptosis is a newly discovered mechanism in cancer immunotherapy; however, cleavage in the N terminus is required to activate pyroptosis. Here, we report a single-agent mRNA nanomedicine-based strategy that utilizes mRNA lipid nanoparticles (LNPs) encoding only the N-terminus of ...
2023年7月15号,新泽西理工学院许晓阳团队和上海交通大学药学院章雪晴团队联合在Nature communications发表文章:mRNA lipid nanoparticle-mediated pyroptosis sensitizes immunologically cold tumors to checkpoint immunotherapy,他们直接向肿瘤组织中递送编码GSD...
近日,上海交通大学章雪晴教授、新泽西理工学院许晓阳教授团队合作,在 Nature Communications 期刊发表了题为:mRNA lipid nanoparticle-mediated pyroptosis sensitizes immunologically cold tumors to checkpoint immunotherapy 的研究论文。 该研究提出了一种基于mRNA的细胞焦亡纳米药物治疗方法,它能够启动癌症免疫周期,将冷肿瘤转化...
2023年7月15号,纽泽西理工学院许晓阳团队和上海交通大学药学院章雪晴团队联合在Nature communications发表文章:mRNA lipid nanoparticle-mediated pyroptosis sensitizes immunologically cold tumors to checkpoint immunotherapy,他们直接向肿瘤组织中递送编码GSDMBNT端结构域的mRNA,无需蛋白酶裂解,便可直接诱导肿瘤细胞焦亡,促进...
2023年7月15号,新泽西理工学院许晓阳团队和上海交通大学药学院章雪晴团队联合在Nature communications发表文章:mRNA lipid nanoparticle-mediated pyroptosis sensitizes immunologically cold tumors to checkpoint immunotherapy,他们直接向肿瘤组织中递送编码GSDMBNT端结构域的mRNA,无需蛋白酶裂解,便可直接诱导肿瘤细胞焦亡,促进释...
et al. Nanoparticle single-cell multiomic readouts reveal that cell heterogeneity influences lipid nanoparticle-mediated messenger RNA delivery. Nat. Nanotechnol. 17, 871–879 (2022). This study reveals that cell subsets have distinct responses to LNPs that may affect mRNA therapies. Article CAS Pub...
Lipid nanoparticle-based mRNA vaccines in cancers: current advances and future prospects. Front Immunol. 2022;13: 922301. Article CAS PubMed PubMed Central Google Scholar Zhang W, Jiang Y, He Y, Boucetta H, Wu J, Chen Z, He W. Lipid carriers for mRNA delivery. Acta Pharm Sin B. ...